Peptide library

MOTS-c claims and the evidence:
mouse findings, no human trial results

Searches for “MOTS-c benefits” lead to claims about metabolism, exercise and ageing. For each claim: the model it was tested in, the sample size, the year, the evidence tier, and what is still unknown.

Short answerCompound research · 6 min read · Updated 18 Nov 2026

The claims made for MOTS-c, about metabolism, exercise capacity and ageing, come from studies in mice and cells. No published study has given MOTS-c to people; a placebo-controlled phase 2a trial began in February 2026 and has no results. Human studies so far measured the body’s own MOTS-c levels, which can show association, not effect.

Key takeaways

  • Claims about MOTS-c fall into three areas, metabolism, exercise capacity and ageing, and the studies that gave it were in mice and cells.
  • The mouse studies, from the group that described MOTS-c, measured weight gain and insulin response on a high-fat diet (2015) and treadmill running at three ages (2021).
  • In old mice, the lifespan result was only a trend, and the authors wrote that larger cohorts are needed.
  • Human studies so far measured natural MOTS-c levels, after exercise or across ages; none gave MOTS-c, and a phase 2a trial is recruiting.
  • FDA staff called the clinical relevance of the animal findings “currently unknown” and the safety risks in people unknown; WADA prohibits MOTS-c at all times.

01MOTS-c claims at a glance: model, sample, tier

Each claim, the main study behind it, and what that study cannot tell you. Dated 18 November 2026; sources at the end of the page.

Area and what was measuredStudyModel and nTierNot known
Metabolism: insulin response, body weightLee et al., 2015Cells; male mice on a high-fat diet, 10 per groupT4, T3Any effect in people; one trial is recruiting
Exercise: treadmill runningReynolds et al., 2021Mice aged 2, 12 and 22 months, 5 to 19 per groupT3Any effect on performance in people
Exercise and natural levelsReynolds et al., 2021; von Walden et al., 202110 young men; 30 adults randomised to exercise or noneT2 (natural levels)Whether a rise matters, or what giving MOTS-c does
Ageing: grip, gait, walking, lifespanReynolds et al., 2021Old male mice started at 23.5 months, 18 treated and 19 controls; 5 to 12 per group in the late-life testsT3Lifespan: a trend only; nothing in people
Ageing: natural levels and genesD’Souza et al., 2020; Fuku et al., 2015Healthy men, 26 per age group; a gene-variant hypothesisT2 (association)Cause and effect

02What did metabolism studies of MOTS-c measure, and in which models?

Cells and mice, 2015 (T4, T3). The paper that described MOTS-c, a 16-amino-acid peptide encoded in mitochondrial DNA, proposed from cell experiments that it acts on the folate cycle and activates AMPK, an enzyme that senses a cell’s energy state, and that skeletal muscle “appears to be” its main target. In male mice on a high-fat diet (N=10 in the paper), the authors reported less weight gain and lower insulin levels than in untreated mice on the same diet, with the same calorie intake; in mice on a normal diet, it had no effect on body weight. In 12-month-old mice (N=6), they reported that muscle took up glucose in response to insulin at levels “comparable to young animals”. One author held shares in and consulted for CohBar, Inc., and another consulted for it.

People: natural levels (T2). A 2018 case-control study in China measured blood MOTS-c in 40 children and adolescents with obesity and 57 controls. Levels were lower in the obesity group, a difference seen in boys but not in girls, and in boys they correlated with markers of insulin resistance. A correlation cannot show that low MOTS-c causes anything, or that giving it would change anything.

A registered trial that gives MOTS-c to people measures insulin sensitivity and has no results yet: see below. The basics of the peptide are in the MOTS-c guide.

03What did exercise studies of MOTS-c measure, and in which models?

Mice, 2021 (T3). The same research group reported better treadmill running in young (2 months), middle-aged (12 months) and old (22 months) mice given MOTS-c, in groups of 5 to 19. Two authors declared consulting roles and shares in CohBar, Inc.

People: natural levels (T2). In the same paper, 10 young men cycled, and MOTS-c rose in their muscle and blood. A 2021 Swedish study randomised 30 adults to endurance exercise, resistance exercise or no exercise (10 each): blood MOTS-c “showed a trend to increase” after endurance exercise, and blood levels were not related to fitness. Neither study gave MOTS-c to anyone.

Sport. WADA names MOTS-c in class S4.4.1, metabolic modulators, among activators of AMPK. It is prohibited at all times in the 2026 and 2027 Lists. See peptides and anti-doping and MOTS-c research.

04What did ageing studies of MOTS-c measure, and in which models?

Mice (T3). In the 2015 paper, MOTS-c levels in muscle and blood were lower in 32-month-old mice than in young ones (3 to 4 per group). In 2021, the group started old male mice on MOTS-c at 23.5 months (18 treated, 19 controls) and, after 30 months of age, reported better grip strength, stride length and 60-second walking results, measured in 5 to 12 mice per group. For lifespan, they reported only “a trend”, and wrote that “larger cohorts will be needed” to confirm it.

People: natural levels (T2). A 2020 study of healthy men aged 18 to 30, 45 to 55 and 70 to 81 (26 per group) found lower MOTS-c in the blood of older men, but about 1.5-fold higher levels in the muscle of middle-aged and older men than in young men. Two authors declared consulting roles and shares in CohBar, Inc.

Genes (T2, hypothesis). A 2015 letter described a variant in the MOTS-c coding region, m.1382A>C, found only in Northeast Asian populations, which the authors had earlier linked to reaching very old age in Japan. They proposed it “may be among” the mechanisms behind long lives in Japan, and wrote that “more research is needed”. More: longevity research.

05Has MOTS-c been tested in people, and what do regulators say?

No published study has given MOTS-c to people (PubMed and ClinicalTrials.gov, 18 November 2026): the five MOTS-c records PubMed indexes as clinical trials all measured natural levels. One trial is registered. NCT07505745 is a phase 2a, randomised, placebo-controlled trial planned for 120 adults with prediabetes and overweight or obesity, measuring an insulin-sensitivity index and adverse events. It began in February 2026 and is recruiting, with no results.

FDA. Reviewing MOTS-c in 2026, FDA staff found “a lack of evidence to evaluate the effectiveness” for the uses nominated. The studies were “limited to in-vitro and in-vivo rodent models”, had not tested how effects change with the amount given, and “the molecular target(s) through which MOTS-c acts remains unknown”, so “the clinical relevance” of the findings “is currently unknown”. They also cited a laboratory study in which MOTS-c is “quickly hydrolyzed in human blood”, which raises the question of whether it reaches active levels in people. On safety, they found no clinical studies or human exposure data, no FAERS reports through 9 March 2025 and no nonclinical toxicity studies, and concluded that “potential safety risks associated with the use of MOTS-c in humans are unknown”. FDA’s compounding page adds that MOTS-c products “may pose significant risk for immunogenicity for certain routes of administration”.

HHS. HHS’s 2026 policy appendix cites “a randomized placebo-controlled trial of a MOTS-c analogue” that “reported no serious adverse events”. It does not name the analogue or the trial, and an analogue is a different molecule. Status by country and the July 2026 committee vote: the MOTS-c guide.

06What we don’t know about MOTS-c

  • Whether any mouse result applies to people. No completed human trial has tested one.
  • Whether MOTS-c given from outside the body reaches active levels in people. FDA staff point to its rapid breakdown in human blood.
  • Which molecule it acts on. FDA staff call its molecular target unknown.
  • What natural MOTS-c levels mean. Level studies show associations, not cause and effect, and they point different ways: older men had lower blood levels but higher muscle levels.
  • How independent the evidence is. The main mouse studies come from the group that described MOTS-c, and three of the papers cited here (2015, 2020, 2021) list authors with consulting roles and shares in CohBar, Inc.

How these tiers are assigned: evidence grades.

This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.

RefSources

  1. Lee C, Zeng J, Drew BG, et al. [Description of MOTS-c, with cell and mouse experiments on metabolism.] Cell Metab, 2015;21(3):443–454. PMID 25738459; full text PMC4350682 read 18 Nov 2026 for group sizes. pubmed.ncbi.nlm.nih.gov/25738459/
  2. Reynolds JC, Lai RW, Woodhead JST, et al. [MOTS-c in mice of different ages, and natural MOTS-c levels in exercising men.] Nat Commun, 2021;12(1):470. PMID 33473109; full text PMC7817689 read 18 Nov 2026. pubmed.ncbi.nlm.nih.gov/33473109/
  3. von Walden F, Fernandez-Gonzalo R, Norrbom J, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol, 2021;131(3):1035–1042. PMID 34351816. pubmed.ncbi.nlm.nih.gov/34351816/
  4. D’Souza RF, Woodhead JST, Hedges CP, et al. Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition. Aging (Albany NY), 2020;12(6):5244–5258. PMID 32182209; full text PMC7138593 read for group sizes. pubmed.ncbi.nlm.nih.gov/32182209/
  5. Du C, Zhang C, Wu W, et al. Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance. Pediatr Diabetes, 2018. PMID 29691953. pubmed.ncbi.nlm.nih.gov/29691953/
  6. Fuku N, Pareja-Galeano H, Zempo H, et al. [Letter on the m.1382A>C mitochondrial DNA variant in the MOTS-c coding region in Japanese people.] Aging Cell, 2015;14(6):921–923. PMID 26289118; full text PMC4693465 read 18 Nov 2026. pubmed.ncbi.nlm.nih.gov/26289118/
  7. ClinicalTrials.gov. NCT07505745: phase 2a, randomised, placebo-controlled study of MOTS-c in adults with prediabetes and overweight or obesity. Registry record, first posted 1 Apr 2026; read 18 Nov 2026. PubMed search the same day: five MOTS-c records indexed as clinical trials, all measuring natural levels. clinicaltrials.gov/study/NCT07505745
  8. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: MOTS-c-related bulk drug substances. Advisory committee briefing, 2026 (pp. 28–31, 33); read 18 Nov 2026. www.fda.gov/media/193347/download
  9. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, Appendix B. Policy document, Oct 2026. hhs.gov returned 403 on 18 Nov 2026; read on the Internet Archive capture of 15 Nov 2026, the newest capture of this URL (p. 9). www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement…
  10. World Anti-Doping Agency. Prohibited List 2026 (in force 1 Jan 2026) and Prohibited List 2027 (in force 1 Jan 2027), class S4.4.1. International Standard; both PDFs read 18 Nov 2026. www.wada-ama.org/en/prohibited-list

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

What do the claims about MOTS-c rest on?

Mouse and cell studies. Claims centre on metabolism, exercise capacity and ageing; no published study has given MOTS-c to people, and FDA staff called the clinical relevance of the animal findings “currently unknown”.

Has MOTS-c been tested in humans?

Not as a given substance in any published study we found (18 Nov 2026). A placebo-controlled phase 2a trial began in February 2026, and earlier human studies measured the body’s own MOTS-c levels.

What is known about MOTS-c side effects?

Very little. FDA staff found no human exposure data and no FAERS reports through March 2025, and called the safety risks in people unknown; FDA’s compounding page says MOTS-c products “may pose significant risk for immunogenicity for certain routes of administration”. HHS cites a trial of an unnamed analogue, a different molecule, that reported no serious adverse events.

Does exercise raise MOTS-c levels?

In 10 young men, levels rose in muscle and blood after cycling; in a 2021 randomised study of 30 adults, the rise after endurance exercise was only a trend. Neither study shows what giving MOTS-c does.

Is MOTS-c prohibited in sport?

Yes. WADA names it in class S4.4.1, metabolic modulators, prohibited at all times in the 2026 and 2027 Lists.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page